David Hung, MD

David Hung, M.D., is a physician (hematology, oncology, transfusion medicine), scientist (molecular biology) and serial biotech entrepreneur who founded Medivation (NASDAQ: MDVN) in October 2003.   Medivation developed and commercialized Xtandi which today is the world’s leading prostate cancer therapy, with over $6 billion in annual revenue.  In October 2016, when Medivation was sold to Pfizer for $14.3 billion in an all-cash deal, it was at the time the largest sale of a biopharma company by an actively-seated founding CEO.

Prior to Medivation, David was President & Chief Executive Officer of Pro•Duct Health, Inc., which developed and commercialized a breast microcatheter — which he himself invented — for a minimally invasive procedure called ductal lavage for early breast cancer detection and risk assessment.  After receiving FDA clearance for the catheter, David sold Pro•Duct Health in 2001 for $168 million to Cytyc Corporation, the world’s leading maker of Pap smears for the cervix, delivering a 10X ROI for his Series A investors in 3 years. 

David is the recipient of numerous distinctions including the Ernst and Young Entrepreneur of the Year Award in the Life Sciences Category as well as Overall US Winner of the Ernst and Young Entrepreneur of the Year Award in 2014 (the world’s most prestigious award in entrepreneurialism), the Pfizer Scholar’s Award (awarded yearly to the top 5 junior academic faculty in a biomedical discipline), the Hulga Irene Duggan Scholar’s Award from the Arthritis Foundation, the Arlo Guthrie Award from the Huntington’s Disease Society of America and the Outstanding Teaching Award for three years in a row from the University California, San Francisco, School of Medicine.

David received his A.B., summa cum laude, in Biology from Harvard College, and his M.D., Alpha Omega Alpha, from the University of California, San Francisco, School of Medicine.